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a  b  s  t  r  a  c  t
Adverse  Events  Following  Immunization  in  Viet  Nam  in  2013  led to  substantial  reductions  in  hepatitis
B  vaccination  coverage  (both  the  birth  dose  and  the  three-dose  series).  In  order  to  estimate  the  impact
of  the reduction  in  vaccination  coverage  on hepatitis  B  transmission  and  future  mortality,  a  widely-used
mathematical  model  was  applied  to  the  data  from  Viet  Nam.  Using  the  model,  we  estimated  the  number
of  chronic  infections  and  deaths  that  are  expected  to  occur  in the  birth  cohort  in 2013  and  the  number  ofeywords:
dverse events following immunization
epatitis B
accination coverage
iet Nam
isease burden
excessive  infections  and  deaths  attributable  to  the drop  in  immunization  coverage  in 2013. An  excess  of
90,137  chronic  infections  and  17,456  future  deaths  were estimated  to  occur  in  the  2013  birth  cohort  due  to
the  drop  in vaccination  coverage.  This  analysis  highlights  the  importance  of  maintaining  high  vaccination
coverage  and  swiftly  responding  to  reported  Adverse  Events  Following  Immunization  in  order  to regain
consumer  conﬁdence  in  the  hepatitis  B vaccine.
©  2015  World  Health  Organization;  licensee  Elsevier.  Published  by  Elsevier  Ltd.  This  is  an  open access
he  CCarticle  under  t
. Introduction
Hepatitis B virus (HBV) infection is a major public health con-
ern in Viet Nam. In adults born before the hepatitis B vaccine was
ntroduced, 7–24% were chronically infected according to several
tudies conducted across the country [1–3]. Perinatal transmis-
ion from infected mothers to infants is common, and more than
alf of the population has been exposed to HBV [2–4]. People who
re infected in infancy usually don’t have symptoms, but 80–90%
ill develop chronic infection that lasts into adulthood [5]. It is
stimated that 20–30% of adults who are chronically infected will
evelop liver cancer or liver cirrhosis [5]. Viet Nam has one of the
ighest liver cancer incidence rates in the world, with an annual
 This is an Open Access article published under the CC BY NC ND 4.0 IGO license
hich permits users to download and share the article for non-commercial pur-
oses, so long as the article is reproduced in the whole without changes, and
rovided the original source is properly cited. This article shall not be used or repro-
uced in association with the promotion of commercial products, services or any
ntity. There should be no suggestion that WHO  endorses any speciﬁc organisation,
roducts or services. The use of the WHO  logo is not permitted. This notice should
e preserved along with the article’s original URL.
∗ Corresponding author. Tel.: +63 2 528 9034.
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ttp://dx.doi.org/10.1016/j.vaccine.2015.05.067
264-410X/© 2015 World Health Organization; licensee Elsevier. Published by Elsev
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
rate of 37.9 per 100,000 population in males [6]. Liver cancer is the
most common cause of cancer deaths in Viet Nam, causing over
20,000 deaths each year [7].
Despite the heavy burden of HBV-related death, new infec-
tions can be effectively prevented through hepatitis B vaccination.
If given within 24 h of birth, the vaccine is highly effective in
preventing mother-to-child transmission [8,9]. The complete series
of 3 doses can provide long term protection [10]. In Viet Nam,
hepatitis B vaccine was  introduced in 1997, and was  expanded
nationwide in 2002 [11]. A birth dose was added to the immuniza-
tion schedule in 2003 [11]. A dramatic reduction in prevalence of
chronic hepatitis B has been observed in children after the intro-
duction of hepatitis B vaccine. A national survey conducted in Viet
Nam in 2011 estimated that children born in 2000–2003 have
signiﬁcantly higher prevalence of chronic HBV infection than chil-
dren born in 2007 to 2008 (3.64% vs. 1.64%) [11]. The same study
found that hepatitis B vaccination coverage increased from 46.1%
to 84.0% for the 3 dose series and from 22.0% to 30.4% for the
birth dose during the same time period [11]. Hence it is evident
that the prevalence of chronic HBV infection can be reduced by
achieving high vaccination coverage. The reduction in hepatitis B
transmission is expected to result in a corresponding reduction
in liver cancer and liver cirrhosis as the new birth cohorts enter
adulthood.
ier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Achieving high vaccination coverage requires both a strong
ystem to deliver the vaccine and high demand for the vaccine.
ublic demand for vaccine is often inﬂuenced by media reports on
llness or deaths after vaccination. Adverse Events Following Immu-
ization (AEFIs) denotes “any untoward medical occurrence” that
ollows immunization, which does not necessarily indicate causal
elationship with vaccination [12]. The events can be purely coin-
idental, but can lead to widespread fears over vaccine safety and
ajor reductions in vaccine demand.
Despite strong efforts to increase hepatitis B vaccination cov-
rage in Viet Nam, publicized news of Adverse Events Following
mmunization (AEFIs) have led to ﬂuctuations in hepatitis B vac-
ination coverage in recent years (Fig. 1). In 2007, the birth dose
overage of hepatitis B vaccine dropped from 64.3% in the previous
ear to 26.9%, partially attributable to media reports of AEFIs. In
013, several AEFIs occurred involving both the hepatitis B mono-
alent vaccine used for the birth dose and the pentavalent vaccine
sed for the 3-dose series. Following these AEFIs, the pentavalent
accine, Quinvaxem (DTwP-HepB-Hib) was suspended from May  to
ctober 2013 [13]. The monovalent hepatitis B vaccine was not sus-
ended. While investigations of the AEFIs did not identify problems
ith the vaccine safety, the widespread media coverage of these
vents led to a major reduction in consumer conﬁdence in the hep-
titis B vaccine. As the public concern over vaccine safety became
ervasive, the hepatitis B birth dose coverage decreased from 75.6%
n 2012 to 56.0% in 2013. This paper estimates the impact of the
eduction in vaccination coverage in 2013 on the number of new
nfections and future deaths related to hepatitis B.
. Methods
.1. Model overview
A published model developed by Goldstein et al. in 2005 was
sed to estimate the expected number of HBV infections and deaths
n children born in 2013 under the reported vaccination coverage
14]. Since the risk of infection and outcome of infection is depend-
nt on age, the model assumes all infections occur in three age
eriods: (1) perinatal infection in infancy, (2) transmission in early
hildhood (<5 years old), and (3) transmission later in life (>5 years
ld). The number of perinatal infections was calculated from the
umber of infants exposed to HBV at birth and the probability of
ransmission. The prevalences reported in studies conducted before
accine introduction were used to estimate annual rate of infec-
ion without vaccination. The number of early childhood infections
as calculated based on the prevalence of anti-HBc at 5 years of
ge, a marker that reﬂects both past and current infection, after
2005 200 6 200 7 200 8 200 9 201 0 2011 201 2 201 3
HepB Birt h Dose 62.3 64.3 26.9 24.5 40.3 21.4 55.0 75.6 56.0
HepB3 93.7 93.2 66.8 86.8 94.5 87.5 95.2 96.6 59.4
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Fig. 1. Administrative coverage of Hepatitis B Vaccine (%) in Viet Nam.(2016) 869–873
excluding the number of children infected at birth. For infection
among individuals aged ﬁve years and above, a constant proportion
of infections occurring each year before the age of 30 was  assumed,
after accounting for age-speciﬁc all-cause mortality. The rate of loss
of chronic infection (HBsAg) was set to 0.5% each year beginning
at the age of 20, and we assumed these people who lost HBsAg
are no longer at risk of HBV-related complications. The probabili-
ties of progressing to acute or chronic infection was assumed to be
only dependent on age and children have much higher probability
of developing chronic infection than adults. Age speciﬁc-mortality
rate of liver cirrhosis and liver cancer was applied to calculate num-
ber of deaths related to chronic hepatitis B. Vaccine efﬁcacy was set
to 95% for both birth dose and the 3-dose series in the base analysis.
The description of the model and parameters can be found in this
paper by Goldstein et al. [14].
2.2. Model input
A literature review was  conducted to determine the sero-
prevalence of HBV infection in children, pregnant women and
adults before the introduction of vaccine using the key words of the
sero-markers and the country’s name. A total of 207 articles were
retrieved from Pubmed, and data from 41 articles that reported
prevalence of the sero-markers were extracted. In the 41 studies,
26 were conducted among Vietnamese immigrants and 15 were
conducted in Viet Nam. Of those conducted in Viet Nam, 7 out
of 15 were conducted among repeated blood donors or liver dis-
ease patients. The remaining 8 studies were among people who are
not expected to be at substantially increased or decreased risk of
hepatitis B infection including 5 community-based studies, 1 study
among potential blood donors, 1 study among non-liver disease
patients and 1 among women  who  attend antenatal care (Table 1)
[1–4,15–18]. None of the studies that reﬂect baseline prevalences
were nationally representative. Only one study conducted in 1999
reported all the data required for the model and this study was
from a community-based random sample consisting of both chil-
dren and adults [16]. In this study, 228 children aged 4 to 6 years
and 596 adults aged 25 to 40 years, including 114 females, were
randomly selected from two districts of Thanh Hoa province [16].
We used the results of this study as model inputs for base analy-
sis. As reported in this study, the prevalence of HBsAg in women
of reproductive age was  15.8%, the prevalence of HBeAg in HBsAg
positive women  was  27.8%, the prevalence of anti-HBc at the age
of 5 was 36.4%, and the prevalence of anti-HBc at the age of 30 was
79.2% [16]. Reported prevalence from the other studies in Table 1
were used for sensitivity analysis.
The numbers of surviving infants and vaccination coverage were
extracted from WHO/UNICEF Joint Reporting Form (JRF) from Viet
Nam of 2013 [19]. According to the JRF reported to WHO  and
UNICEF by Viet Nam Ministry of Health, the total number of sur-
viving infants in 2013 was 1782,720. The hepatitis B vaccination
coverage for the birth dose was  56.0% and that for the complete
series of at least three doses (HepB3) was 59.4% [19].
General mortality rate was derived from World Population
Prospects 2012 Revision, published by United Nations Population
Division. The estimated age-speciﬁc death rates in Viet Nam in
2005–2010 were used [20].
2.3. Sensitivity analysis
A univariate sensitivity analysis was  performed to examine the
impact of uncertainty in the model inputs and vaccine efﬁcacy:
HBsAg prevalence in pregnant women, HBeAg prevalence in HBsAg
positive women, anti-HBc prevalence at the age of 5 years and at
the age of 30 years, birth dose vaccine efﬁcacy and efﬁcacy of the
complete series. Each parameter was  changed one at a time, while
X. Li et al. / Vaccine 34 (2016) 869–873 871
Table  1
Prevalence of HBV serological markers from studies conducted in Viet Nam.a
Authors Year of survey Study population Overall
sample size
HBsAg(+) in
women of
reproductive
age (%)
HBeAg(+) in
HBsAg(+) women
(%)
Anti-HBc (+) in
children aged 5 (%)
Anti-HBc(+) in
adults (%)
Do et al. [4] 2012 Adults randomly selected in
Binh Thuan province
509 20b NA NA 71.7
Le  Viet et al. [15] 2007 Potential voluntary blood
donors in two  rural
communities in Quang Tri
province
1200 7.9 NA NA 51.7
Nguyen et al. [3] 2002 Adults randomly selected in
two rural districts in Thai Binh
province
837 24c 21.4c NA 68.2
Duong et al. [2] 2006 Adults randomly selected in
Linhson village, Thainguyen
province
383 8.8 38.2e NA 66.2
Lan  et al. [1] 2006 Married women  aged 18–39
years in FilaBavi
606 7.1 NA NA NA
Goto  et al. [18] 2003 Pregnant women 15–49 years
of age attending antenatal care
in 4 districts in Nghe An
Province
505 10 NA NA NA
Hipgrave et al. [16] 1998 Children and adults randomly
selected from two  districts of
Thanh Hoa province
1579 15.8 27.8 36.4 79.2
Nakata et al. [17] 1993 Pregnant women and patients
without liver diseases in Hanoi
and Ho Chi Minh
591 14d NA 34.8f NA
a Where necessary, recalculations from the original publications were conducted to obtain estimates of interest.
b Estimate included both men  and women aged 20–39 years.
c Estimate included both men  and women aged 20–29 years.
d Estimate included both men  and women aged 16 years and above.
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sitivity analysis, which means the deaths that could have been
prevented if the vaccination coverage had been maintained at 2012
level. Assuming no catch-up immunization, the number of exces-
sive deaths due to the drop in vaccination coverage ranged frome Estimate includes all HBsAg positive participants (men and women aged 18–70
f The estimate presented is a proxy using the sum of anti-HBs positive or HBsAg 
am.
thers remained constant. The highest and lowest reported preva-
ence in the studies presented in the supplementary table were
sed to calculate the high and low estimates of chronic HBV infec-
ion and deaths caused by HBV infection. When the prevalence
stimates in the base analysis are the highest among all reported
alues, in the case of anti-HBc prevalence at 5 years of age and
nti-HBc at 30 years of age, 5% was added to the base prevalence
o calculate the high estimate. Based on published trials [8,9], the
ower estimate of vaccine efﬁcacy was set to 80% for both the birth
ose and the 3-dose series, and the upper limit of vaccine efﬁcacy
or both birth dose and the 3-dose series was set to 98%, considering
hances of break-through infections and non-response.
. Results
The model estimated the number of chronic infections and
eaths that are expected with varied vaccination coverage in chil-
ren born in 2013 (Table 2). Without vaccination, among children
orn in 2013, a total of 293,676 chronic HBV infections and 56,655
eaths caused by HBV are expected in their lifetime if they pass
hrough their life under the currently observed mortality rates. In
013, the reported birth dose coverage is 56.0% and HepB3 coverage
s 59.4%. With the reported coverage, 130,675 chronic infections
nd 25,197 deaths are expected among this birth cohort as they
ass through their life. Among them, 29.3% of chronic infections
nd 28.6% of expected deaths are due to perinatal infection, 55.7% of
hronic infections and 54.9% of expected deaths are due to horizon-
al transmission before the age of 5, and 16.6% of chronic infections
nd 15.0% of expected deaths are due to horizontal transmission
fter the age of 5. This suggests catch-up immunization activities
n these young children could prevent over half of the expected
eaths.).
e participants aged 1–10 years who were born before vaccine introduction in Viet
If the vaccination coverage had been maintained at the same
level as in 2012 (birth dose coverage 75.6%, HepB3 coverage 96.6%),
40,538 chronic infections and 7741 deaths are expected. This sug-
gests 90,137 excessive chronic infections and 17,456 deaths would
occur due to the drop in vaccination coverage in 2013, if no catch-up
immunization is to be conducted in this birth cohort.
If the birth dose coverage and HepB3 coverage could both reach
the regional target of 95% while the size of birth cohorts remains
constant, 51,131 deaths could be prevented and 265,043 chronic
infections could be avoided every year through immunization.
Fig. 2 presents the number of excessive deaths from the sen-Fig. 2. Sensitivity analysis: number of excess deaths expected due to AEFI.
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Table 2
Number of chronic hepatitis B infections and deaths expected with varied vaccination coverage*.
Vaccination coverage Without vaccination Regional target Maintaining 2012 coverage 2013 coverage after AEFI
Birth dose 0.0% 95.0% 75.6% 56.0%
HepB3  0.0% 95.0% 96.6% 59.4%
Number of chronic infections 293,676 28,633 40,538 130,675
Number of deaths
Acute 1181 115 98 515
Liver  cirrhosis 28,126 2742 3874 12,514
Hepatocellular carcinoma 27,348 2666 3770 12,168
Total  deaths 56,655 5524 7741 25,197
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a* Assuming HBsAg% in women  of reproductive age = 15.8%, HBeAg% in HBsAg p
lds  = 79.2%, birth dose efﬁcacy = 95% and complete vaccine series efﬁcacy = 95%.
5,151 to 19,279, and the number of excessive chronic infections
anged from 78,304 to 97,703 as the model input changed between
owest and highest estimates.
. Discussion
Based on the model, an estimated 130,675 chronic HBV infec-
ions and 25,197 HBV-related deaths would occur in children born
n 2013. If the hepatitis B vaccination coverage had been main-
ained at the same level as in 2012, 90,137 chronic infections and
7,456 deaths would have been avoided. The results suggest a dra-
atic increase in hepatitis B disease burden caused by the drop in
accination coverage.
Although the hepatitis B vaccine is one of the safest vaccines
vailable, media coverage of AEFIs can lead to major reductions in
accination coverage. Following the 2013 AEFI investigation, which
etermined that the AEFIs were the result of human error, the
ational Institute of Hygiene and Epidemiology held several meet-
ngs with journalists from major newspapers to develop accurate
nd easily understood messages for the public. However it was not
ossible to meet with all media and some media sources reported
hat the AEFIs were due to the vaccine. In 2013 the pervasive news
eports of the AEFIs in Viet Nam led to a widespread reduction in
epatitis B vaccine demand. This study demonstrates the devas-
ating consequences of a loss in public conﬁdence in the hepatitis
 vaccine. To avoid the future burden caused by this preventable
isease, it is imperative to restore public conﬁdence in vaccination.
The timing of the ﬁrst dose of the vaccine, in the ﬁrst 24 h of life,
oincides with the most fragile period in infancy. Infant mortality
n Viet Nam is estimated to be 16 per 1000 live births [20]. This
quates to 28,523 infant deaths in 2013. It is easy for concerned
arents or the media to suggest that vaccination is responsible for
nfant deaths. Major efforts are needed to mitigate the impact of
edia reports of AEFIs on vaccine demand. These include educat-
ng the media on vaccine safety, swiftly investigating reported AEFI
ases, and openly informing the public of the results of the investi-
ation. One challenge to conducting AEFI investigations is the lack
f evidence about causes of death in cases when no autopsy is done
as was the case for the 2007 AEFIs). It is not easy to communicate
ith the public without sound evidence about the causes of the
EFIs. The National Institute of Hygiene and Epidemiology there-
ore advises parents to immediately bring children with severe
ymptoms after immunization to a hospital for diagnosis and treat-
ent.
The results suggest the great potential of hepatitis B control
hrough immunization: if Viet Nam could reach the target of 95%
overage of both birth dose and HepB3, about 51,131 future deaths
nd 265,043 chronic infections can be prevented each year by vac-
ination. The national sero-survey in children conducted in 2011
howed the signiﬁcantly lower prevalence of chronic hepatitis B
fter the introduction of hepatitis B vaccine. The experience from women = 27.8%, anti-HBc% among 5-year olds = 36.4%, anti-HBc% among 30-year
other countries in the region demonstrates that the regional goal
to reduce prevalence of chronic hepatitis B infection to less than
1% in children can be achieved by maintaining high vaccination
coverage.
So far there has not been a national sero-survey among adults
in Viet Nam. The model parameters used in the base analysis
were derived from one survey in two rural districts in north-
ern Viet Nam, which can lead to potential bias. The two  districts
were inhabited by two  ethnic groups, Kinh and Muong. The study
found high prevalence of chronic hepatitis B among adults in both
the national dominant Kinh ethnic group (19.6%) and the minor-
ity Muong (17.8%). Varied prevalences of hepatitis B have been
reported in different provinces in Viet Nam [1–3,11,15–18]. The
base analysis used the HBsAg prevalence of 15.8% among women,
which is around the midpoint of the reported range (7.1% to 24%)
in studies that sampled general population from communities. The
sensitivity analysis suggests the model is robust with large changes
in model parameters. When the model inputs changed from lowest
to highest estimates, the number of excessive deaths changed from
15,151 to 19,279.
Uncertainties exist in vaccination coverage and size of birth
cohort. We  noticed different numbers of birth cohort size were
reported in the JRF and United Nations Population Division esti-
mates, and the birth dose coverage reported in JRF is different from
that in WHO  and UNICEF Estimates of National Immunization Cov-
erage (WUENIC) [19–21]. Estimating numbers of births and infant
deaths is challenging in many low and middle-income countries
including Viet Nam, where vital registration is incomplete [22]. We
used number of surviving infants reported by JRF in the model since
we consider this better reﬂects local situation. Administrative cov-
erage of birth dose reported in JRF was used in the analysis since
recent coverage estimated by national representative surveys is still
not available, and the calibration in the WUENIC derived from a
2008 survey is less relevant to the situation in 2013.
The model does not take into account the protective effect of
incomplete vaccine series or the effect of the birth dose against
early childhood transmission, which may  lead to underestimate
of impact of vaccination. The model only considers the effect of
full vaccine series in preventing transmission after birth, while the
dropout between the ﬁrst dose and the third dose of the penta-
valent vaccine was particularly large (24%) in 2013. These children
who received less than 3 doses may  develop some partial immunity
from incomplete series received before their vaccination was inter-
rupted by the events. However, since limited data are available on
efﬁcacy of incomplete vaccination, the effect of incomplete vaccine
series was  not quantiﬁed by the model. The model may overesti-
mate the impact of birth dose, since it assume a single birth dose to
be 95% efﬁcacious of preventing perinatal infection, regardless of
whether subsequent doses are received. Yet our sensitivity analy-
sis suggests, even if the birth dose efﬁcacy is 80%, 17, 004 excessive
deaths are still attributable to the drop in vaccination coverage.
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As additional data become available, the accuracy of model input
ay  be improved and the estimates can be compared to measured
hronic hepatitis B prevalence and hepatitis B-related mortality.
et, our result suggests even with the most conservative parame-
ers, more than 15,000 lives could have been saved in the 2013 birth
ohort in Viet Nam if the vaccination coverage had been maintained
t the 2012 level.
These ﬁndings may  be used in different channels to com-
unicate with policy makers and the public on the beneﬁts of
accination and consequences of non-vaccination. Some suggested
ses include presenting the ﬁndings at workshops and trainings
ith health workers and EPI staff, sending letters explaining ﬁnd-
ngs to policy makers, mass media communication (press releases,
orkshops, TV talk shows, coverage in daily newspapers, Q&A
n websites), dissemination to professional societies such as the
ietnam Association of Preventive Medicine, presenting the ﬁnd-
ngs in government meetings (such as Parliament Committee of
ocial Affairs, Prime Minister, Government Cabinet, and Finance
inistry), and sharing the ﬁndings with international partners in
he Interagency Coordinating Committee meetings (WHO, UNICEF,
AVI, WB,  ADB, JICA, and PATH).
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